Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,436.00 +54.65 (+0.65%) Bitcoin USD
63,035.00 +1,898.81 (+3.11%) CMC Crypto 200
1,302.53 -55.48 (-4.09%)
Telomir Pharmaceuticals, Inc. (TELO)
| Previous close | 6.49 |
| Open | 6.80 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 6.21 - 7.40 |
| 52-week range | 4.76 - 20.72 |
| Volume | |
| Avg. volume | 60,519 |
| Market cap | 210.23M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.
Telomir-1 elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase that protects the DNA and genetic material in chromosomes to combat aging Demonstrated a 40% increase in telomerase activity and lengthened telomeres in vitro in human cells Provided pre-clinical endpoints to determine “anti-aging” and “age-reversal” effects in dogs Outlined timeline for initiating human investigational new drug (IND) trials for osteoarthritis, along with animal IND
- GlobeNewswire
Telomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024
Telomir’s pre-clinical studies demonstrate its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase New York Times article supports belief that telomere shortening reduces longevity BALTIMORE, April 02, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as t
- GlobeNewswire
UPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines
Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases This study is believed to be the first and only known study focused on reversing aging in canines BALTIMORE, March 29, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the
